Valinor Pharma

News

Grünenthal's chief executive Gabriel Baertschi

Grünenthal buys Valinor and constipation drug for $250m

German pain medicines specialist Grünenthal has dipped another toe in the M&A waters with a $250 million agreement to buy US drugmaker Valinor Pharma.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks